Merck Animal Health Launches High Quality Congress Website
Congresses Continue to Support Aquaculture, Poultry and Swine Customers
MADISON, N.J., November 24, 2015 –Merck Animal Health (known as MSD Animal Health outside the USA and Canada) today announced the launch of its High Quality Congress website to support producers of aquaculture, poultry and swine. Since 2012, Merck Animal Health’s High Quality Congresses have served the industry by bringing together a wide range of experts to discuss the latest advances in production and management across these species to ensure the success of producers by improving health, productivity and well-being of their animals.
“As our customers strive to meet growing consumer demand for safe, quality and affordable protein, as well as transparency in the way animals are raised, Merck Animal Health is playing a decisive role in helping them succeed,” said Fabio Paganini, Food Production Animal Business Unit, Merck Animal Health. “We are committed to innovating new solutions and providing value-added services such as the High Quality Congresses that can help producers provide high quality meat and continually earn the confidence of their customers.”
By visiting HighQualityCongress.com, producers can access news about upcoming and past Congresses, as well as a repository of information about Merck Animal Health programs and technologies, including The Convenience Program®, a hatchery-oriented service delivering early protection for a more robust business; Go Beyond, a performance program that helps poultry producers improve food safety and intestinal health expertise; RESPIG®, a dedicated swine health service that provides cutting-edge insights on many complex respiratory diseases; and the ReproPig® Management System that allows producers to explore and optimize their herd’s reproductive performance.
“Merck Animal Health is pleased to serve the industry through our ongoing leadership and innovation in disease prevention and animal well-being,” said Paganini. “We will continue to provide the services and solutions our customers need to meet the world’s growing demand for quality protein.”
More than 3,000 industry professionals from nearly 100 countries have participated in 18 High Quality Congresses since the program’s inception. For more information, please visit http://highqualitycongress.com/.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).